Anti-idiotype cancer vaccine 105AD7

Drug Profile

Anti-idiotype cancer vaccine 105AD7

Alternative Names: 105AD7; Onyvax-105

Latest Information Update: 05 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Nottingham
  • Developer Cancer Research Technology; National Cancer Institute (USA); Onyvax
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 31 May 2007 A second-generation version of Onyvax 105 is being developed, which will enter preclinical development
  • 05 Mar 2004 Phase-I clinical trials in Sarcoma in United Kingdom (Parenteral)
  • 02 Jun 2000 Onyvax has been awarded a US patent covering 105AD7
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top